Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Neurology
•
Neuro-immunology
Would you consider anti-CD20 agents for treatment of multiple sclerosis in patients with history of breast cancer?
Related Questions
Are there any precautions that should be taken when transitioning a patient with multiple sclerosis from one disease modifying therapy to another?
How do you decide on initial and sequential anti-CD20 therapy for patients with multiple sclerosis given the availability of rituximab, ocrelizumab, ublituximab, and ofatumumab?
When do you start cyclophosphamide for the treatment of anti-NMDA receptor encephalitis?
For patients on anti-CD20 therapy for MS without frequent/opportunistic infections, are there serum IgG levels or ALC levels in which you pause or change therapy due to low levels?
Can you use a JAK inhibitor and Mavenclad in a patient with both multiple sclerosis and rheumatoid arthritis?
How would you treat chorea in a patient with Sjögren’s syndrome and positive beta 2 glycoprotein I antibodies?
How do you counsel patients who experience diarrhea from mycophenolate mofetil (Cellcept)?
Can you use leflunomide and rituximab in a patient with both multiple sclerosis and rheumatoid arthritis?
Do you treat tumefactive multiple sclerosis differently than other forms of MS both in the acute and maintenance phase?
How does one interpret an SPEP showing potentially obscured but non-quantifiable M-spike however an IFE showing monoclonal protein?
